Selective Class I Histone Deacetylase Inhibition Suppresses Hypoxia-Induced Cardiopulmonary Remodeling Through an Antiproliferative Mechanism

被引:156
作者
Cavasin, Maria A. [1 ]
Demos-Davies, Kim [1 ]
Horn, Todd R. [1 ]
Walker, Lori A. [1 ]
Lemon, Douglas D. [1 ]
Birdsey, Nicholas [2 ]
Weiser-Evans, Mary C. M. [3 ]
Harral, Julie [4 ]
Irwin, David C. [1 ]
Anwar, Adil [4 ]
Yeager, Michael E. [4 ]
Li, Min [4 ]
Watson, Peter A. [2 ,5 ]
Nemenoff, Raphael A. [3 ]
Buttrick, Peter M. [1 ]
Stenmark, Kurt R. [4 ]
McKinsey, Timothy A. [1 ]
机构
[1] Univ Colorado Denver, Dept Med, Div Cardiol, Aurora, CO 80045 USA
[2] Univ Colorado Denver, Div Endocrinol Metab & Diabet, Aurora, CO 80045 USA
[3] Univ Colorado Denver, Div Renal Dis & Hypertens, Aurora, CO 80045 USA
[4] Univ Colorado Denver, Dept Pediat, Div Pulm & Crit Care Med, Aurora, CO 80045 USA
[5] Denver VA Med Ctr, Denver, CO USA
关键词
histone deacetylase; pulmonary hypertension; proliferation; gene expression; signaling pathways; PULMONARY-HYPERTENSION; HDAC INHIBITORS; SURVIVAL; PROLIFERATION; INFLAMMATION; HYPERTROPHY; ACTIVATION; EMERGENCE; GROWTH;
D O I
10.1161/CIRCRESAHA.111.258426
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: Histone deacetylase (HDAC) inhibitors are efficacious in models of hypertension-induced left ventricular heart failure. The consequences of HDAC inhibition in the context of pulmonary hypertension with associated right ventricular cardiac remodeling are poorly understood. Objective: This study was performed to assess the utility of selective small-molecule inhibitors of class I HDACs in a preclinical model of pulmonary hypertension. Methods and Results: Rats were exposed to hypobaric hypoxia for 3 weeks in the absence or presence of a benzamide HDAC inhibitor, MGCD0103, which selectively inhibits class I HDACs 1, 2, and 3. The compound reduced pulmonary arterial pressure more dramatically than tadalafil, a standard-of-care therapy for human pulmonary hypertension that functions as a vasodilator. MGCD0103 improved pulmonary artery acceleration time and reduced systolic notching of the pulmonary artery flow envelope, which suggests a positive impact of the HDAC inhibitor on pulmonary vascular remodeling and stiffening. Similar results were obtained with an independent class I HDAC-selective inhibitor, MS-275. Reduced pulmonary arterial pressure in MGCD0103-treated animals was associated with blunted pulmonary arterial wall thickening because of suppression of smooth muscle cell proliferation. Right ventricular function was maintained in MGCD0103-treated animals. Although the class I HDAC inhibitor only modestly reduced right ventricular hypertrophy, it had multiple beneficial effects on the right ventricle, which included suppression of pathological gene expression, inhibition of proapoptotic caspase activity, and repression of proinflammatory protein expression. Conclusions: By targeting distinct pathogenic mechanisms, isoform-selective HDAC inhibitors have potential as novel therapeutics for pulmonary hypertension that will complement vasodilator standards of care. (Circ Res. 2012;110:739-748.)
引用
收藏
页码:739 / U250
页数:22
相关论文
共 33 条
[1]   Suppression of Histone Deacetylases Worsens Right Ventricular Dysfunction after Pulmonary Artery Banding in Rats [J].
Bogaard, Harm J. ;
Mizuno, Shiro ;
Al Hussaini, Ayser A. ;
Toldo, Stefano ;
Abbate, Antonio ;
Kraskauskas, Donatas ;
Kasper, Michael ;
Natarajan, Ramesh ;
Voelkel, Norbert F. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183 (10) :1402-1410
[2]   Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor [J].
Boumber, Yanis ;
Younes, Anas ;
Garcia-Manero, Guillermo .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (06) :823-829
[3]   Chemical phylogenetics of histone deacetylases [J].
Bradner, James E. ;
West, Nathan ;
Grachan, Melissa L. ;
Greenberg, Edward F. ;
Haggarty, Stephen J. ;
Warnow, Tandy ;
Mazitschek, Ralph .
NATURE CHEMICAL BIOLOGY, 2010, 6 (03) :238-243
[4]   Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a) [J].
Brunet, A ;
Park, J ;
Tran, H ;
Hu, LS ;
Hemmings, BA ;
Greenberg, ME .
MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (03) :952-965
[5]   Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor [J].
Brunet, A ;
Bonni, A ;
Zigmond, MJ ;
Lin, MZ ;
Juo, P ;
Hu, LS ;
Anderson, MJ ;
Arden, KC ;
Blenis, J ;
Greenberg, ME .
CELL, 1999, 96 (06) :857-868
[6]   Protein Acetylation in the Cardiorenal Axis The Promise of Histone Deacetylase Inhibitors [J].
Bush, Erik W. ;
McKinsey, Timothy A. .
CIRCULATION RESEARCH, 2010, 106 (02) :272-284
[7]   Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy [J].
Cao, Dian J. ;
Wang, Zhao V. ;
Battiprolu, Pavan K. ;
Jiang, Nan ;
Morales, Cyndi R. ;
Kong, Yongli ;
Rothermel, Beverly A. ;
Gillette, Thomas G. ;
Hill, Joseph A. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (10) :4123-4128
[8]   Sodium Valproate, a Histone Deacetylase Inhibitor, but Not Captopril, Prevents Right Ventricular Hypertrophy in Rats [J].
Cho, Young Kuk ;
Eom, Gwang Hyeon ;
Kee, Hae Jin ;
Kim, Hyung-Seok ;
Choi, Woo-Yeon ;
Nam, Kwang-Il ;
Ma, Jae Sook ;
Kook, Hyun .
CIRCULATION JOURNAL, 2010, 74 (04) :760-770
[9]   SURVIVAL IN PATIENTS WITH PRIMARY PULMONARY-HYPERTENSION - RESULTS FROM A NATIONAL PROSPECTIVE REGISTRY [J].
DALONZO, GE ;
BARST, RJ ;
AYRES, SM ;
BERGOFSKY, EH ;
BRUNDAGE, BH ;
DETRE, KM ;
FISHMAN, AP ;
GOLDRING, RM ;
GROVES, BM ;
KERNIS, JT ;
LEVY, PS ;
PIETRA, GG ;
REID, LM ;
REEVES, JT ;
RICH, S ;
VREIM, CE ;
WILLIAMS, GW ;
WU, M .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (05) :343-349
[10]   Histone Deacetylase Inhibitors for Treating a Spectrum of Diseases Not Related to Cancer [J].
Dinarello, Charles A. ;
Fossati, Gianluca ;
Mascagni, Paolo .
MOLECULAR MEDICINE, 2011, 17 (5-6) :333-352